MedPath

Cough Responses to Tussive Agents in Health and Disease

Completed
Conditions
Chronic Obstructive Airway Disease
Chronic Cough
Asthma
Interventions
Other: Cough Challenge Tests
Other: ambulatory cough recording
Other: Cough questionnaires
Registration Number
NCT01297790
Lead Sponsor
Manchester University NHS Foundation Trust
Brief Summary

The sensitivity of a persons cough reflex can be measured by getting them to breath in (inhale) irritant chemicals. The purpose of this clinical research study is to test the sensitivity of the cough reflex to a variety of chemicals that can be inhaled to see if coughing responses are different between healthy people and people with respiratory problems that make them cough.

Detailed Description

Coughing is a distressing symptom which has a major impact on quality of life. It has been estimated that cough costs the UK economy £1 billion each year. Currently there are no effective anti-tussive agents to treat subjects with cough. Although drugs such as morphine may have some anti-tussive effect, side effects unacceptable.

Currently our understanding of the mechanisms which lead to coughing in different diseases is poor. Many mechanistic studies rely on testing the sensitivity of the cough reflex by inhalation of capsaicin (chilli-pepper extract) or citric acid. These challenges do not differentiate well between health and disease or between different disease states. Other agents such as prostaglandins and bradykinin are known to stimulate a coughing but responses to these agents have rarely been used as a measure of cough reflex sensitivity and not been compared to standard challenges.

It is clear that patients with common airway diseases such as COPD and asthma cough significantly more than healthy subjects. Moreover subjects presenting with chronic cough have cough rates an order of magnitude higher than most patients with airway disease. These differences are poorly represented by the differences in current cough challenge tests.

The investigators hypothesize that patterns of cough responses to different tussive agent may better differentiate between health and different disease states. These patterns may also suggest the different mechanisms leading to cough in different diseases.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
102
Inclusion Criteria
  • General

    • Adult subjects aged 18 years and over

    • Meet criteria for subject groups as outlined below

      (1) Healthy volunteers

    • Non-smokers

    • No history of respiratory disease

      (2) Healthy smokers

    • Current smokers with smoking history of ≥10 pack years

    • Spirometry within normal limits i.e. FEV1>80% predicted and FEV1/FVC ratio >75% predicted

      (3) Asthma

    • Physician diagnosis of asthma

    • Airways hyperresponsiveness to methacholine; PC20<16mg/ml (within last 2 years)

    • Non-smokers or ex-smoker with smoking history of ≤10 pack years

      (4) COPD

    • Physician diagnosis of COPD

    • Ex-smokers with smoking history of ≥20 pack years

    • Spirometry demonstrating airflow obstruction i.e. FEV1/FVC ratio <70%

      (5) Chronic Cough

    • History of a dry cough for >8 weeks

    • Normal CXR

    • Non-smokers or ex-smoker with smoking history of ≤10 pack years

Exclusion Criteria
    1. Symptoms of upper respiratory tract infection within the last 6 weeks 2) Participation in another clinical trial of an investigational drug within the last 4 weeks 3) Use of medication likely to alter cough reflex sensitivity i.e. ACE inhibitors, codeine phosphate, morphine sulphate, 4) Patients with severe respiratory disease i.e. FEV1 < 1 litre, 5) Significant medical co-morbidities likely to affect ability to participate in the trial or affect cough reflex sensitivity e.g. diabetes, stroke, Parkinson's disease, multiple sclerosis etc.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Chronic coughCough questionnairesSubjects with idiopathic chronic cough.
Healthy VolunteersCough Challenge TestsHealthy non smoking adults.
Asthmaambulatory cough recordingSubjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
Healthy Volunteersambulatory cough recordingHealthy non smoking adults.
Chronic coughambulatory cough recordingSubjects with idiopathic chronic cough.
Chronic obstructive pulmonary diseaseCough Challenge TestsSubjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
Chronic obstructive pulmonary diseaseCough questionnairesSubjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
Healthy smokersCough Challenge TestsCurrent smokers with normal breath tests (spirometry)
Healthy smokersambulatory cough recordingCurrent smokers with normal breath tests (spirometry)
AsthmaCough Challenge TestsSubjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
AsthmaCough questionnairesSubjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
Chronic obstructive pulmonary diseaseambulatory cough recordingSubjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
Healthy VolunteersCough questionnairesHealthy non smoking adults.
Healthy smokersCough questionnairesCurrent smokers with normal breath tests (spirometry)
Chronic coughCough Challenge TestsSubjects with idiopathic chronic cough.
Primary Outcome Measures
NameTimeMethod
Objective cough recording24 Hours

To perform ambulatory cough recording over 24 hours to assess if there are any differences

Cough response to tussive agents45 minutes

To measure cough responses to capsaicin, citric acid, prostaglandin E2 (PGE2) and Bradykinin (BK) in healthy volunteers, airway diseases (asthma and COPD) and chronic cough.

To compare the ability of individual challenges and patterns of challenge response to discriminate between diagnostic groups.

Secondary Outcome Measures
NameTimeMethod
C2 to inhaled tussive agents45 minutes

C2 concentration difference between different diagnostic groups after inhalation of tussive agents

Trial Locations

Locations (1)

University Hospital of South Manchester

🇬🇧

Manchester, Lancashire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath